CollPlant Biotechnologies (NASDAQ:CLGN) Shares Down 0.8% – Here’s What Happened

CollPlant Biotechnologies Ltd. Sponsored ADR (NASDAQ:CLGN)’s stock price was down 0.8% during trading on Friday . The company traded as low as $1.82 and last traded at $1.89. Approximately 13,975 shares changed hands during mid-day trading, a decline of 34% from the average daily volume of 21,180 shares. The stock had previously closed at $1.9060.

Analyst Upgrades and Downgrades

CLGN has been the subject of several recent analyst reports. D. Boral Capital reaffirmed a “buy” rating and set a $12.00 price objective on shares of CollPlant Biotechnologies in a report on Friday, November 28th. Weiss Ratings restated a “sell (e+)” rating on shares of CollPlant Biotechnologies in a research report on Wednesday, January 21st. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, CollPlant Biotechnologies has an average rating of “Hold” and a consensus target price of $11.50.

CollPlant Biotechnologies Trading Down 0.8%

The stock has a 50 day moving average price of $1.71 and a two-hundred day moving average price of $2.17. The company has a market cap of $24.15 million, a price-to-earnings ratio of -1.85 and a beta of 1.47.

CollPlant Biotechnologies (NASDAQ:CLGN) last issued its earnings results on Wednesday, November 26th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.38 by ($0.65). The company had revenue of $0.08 million for the quarter, compared to the consensus estimate of $16.52 million. CollPlant Biotechnologies had a negative return on equity of 102.00% and a negative net margin of 491.31%. On average, equities analysts forecast that CollPlant Biotechnologies Ltd. Sponsored ADR will post -1.44 EPS for the current fiscal year.

Institutional Trading of CollPlant Biotechnologies

Large investors have recently made changes to their positions in the company. Villere ST Denis J & Co. LLC lifted its holdings in CollPlant Biotechnologies by 3.2% during the fourth quarter. Villere ST Denis J & Co. LLC now owns 607,300 shares of the company’s stock worth $850,000 after acquiring an additional 18,583 shares in the last quarter. Pinnacle Associates Ltd. raised its position in shares of CollPlant Biotechnologies by 3.7% during the second quarter. Pinnacle Associates Ltd. now owns 507,193 shares of the company’s stock worth $690,000 after purchasing an additional 18,000 shares during the period. Finally, AMH Equity Ltd raised its position in shares of CollPlant Biotechnologies by 24.3% during the third quarter. AMH Equity Ltd now owns 200,000 shares of the company’s stock worth $538,000 after purchasing an additional 39,151 shares during the period. Institutional investors own 21.69% of the company’s stock.

CollPlant Biotechnologies Company Profile

CollPlant Biotechnologies Ltd. (NASDAQ: CLGN) is a regenerative medicine company that develops and commercializes recombinant human collagen (rhCollagen) and 3D bioprinting technologies for medical and aesthetic applications. The company’s proprietary plant-based rhCollagen is produced using genetically engineered tobacco plants to provide a scalable, animal-free source of human collagen that meets regulatory standards.

CollPlant’s product portfolio includes Vergenix™ wound care matrices and dermal fillers for aesthetic and reconstructive purposes, as well as a range of bioinks designed for 3D bioprinting of soft and hard tissues.